BEARINGPOINT
17.9.2020 08:57:22 CEST | Business Wire | Press release
Management and technology consultancy BearingPoint announced today that it has acquired Paris-based Steerio, an engagement platform (SaaS) that leverages smart analytics to push teamwork, feedback and decision-making into the digital age. With the acquisition, BearingPoint expands its portfolio of team and project management assets and enhances its People & Strategy offering that focuses on the people dimension of a company’s strategy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200916005793/en/
The acquisition is part of a bigger strategic move: the independent consulting firm has been investing for years in new and better ways of working. This includes innovative project and team management and collaboration solutions across business units, countries and teams for more innovation, agile-working, and remote and mobile working - an approach embedded in the firm’s Strategy 2025, which puts people in the center. To accelerate this ambition, BearingPoint also created and included data-driven digital assets and managed services in its portfolio.
Steerio joins BearingPoint’s portfolio of team and project management assets such as Active Manager and enhances its People & Strategy offering. BearingPoint said Steerio will be rolled out to all projects of a certain size and complexity and will form a substantial pillar of the way the firm delivers consulting projects.
“The new normal demands that we create and bring to life new ways of working and related offerings,” said Kiumars Hamidian, Managing Partner BearingPoint. “Putting people in the center is a major ambition driving our Strategy 2025, and the acquisition of Steerio fits well with our portfolio of offerings because Steerio is both people-centric and data-driven at the same time. The Steerio platform opens even more innovative ways to collaborate across teams and firms for the best possible outcomes for our clients.”
“Working and collaboration in the 'new normal' is more important than ever, and Steerio’s smart analytics create an augmented project experience for all our team members, which we especially need in these times of remote working,” adds Damien Palacci, Global Leader Consulting Portfolio at BearingPoint. “It is another tool for us to use and leverage for better teamwork, knowledge transfer, and more innovation. And it also empowers employees and helps them take ownership and be entrepreneurs.”
Steerio captures weak signals and uses “soft-data” analytics and best-practices and team feedback to identify roadblocks and adopt best-practices proactively to secure team effectiveness. It reduces project failure and delays and promotes transparency and trust. Every stakeholder has access to anonymized and objective team results.
“Becoming part of BearingPoint is a giant leap for us, as it significantly increases our ability to provide a wider array of services to our clients,” said Damien Guery, Co-Founder of Steerio. “We can now combine our expertise and assets and leverage them with BearingPoint's extensive industry network. We are going to be able to push teamwork and decision-making into the digital age.”
About Steerio
Paris-based Steerio was started to bring teamwork, feedback and decision-making to the digital age, combining years of practical experience, best-practice methodologies and knowledge in artificial intelligence. By leveraging new types of data and enabling decision makers to access the relevant insights at the right time, Steerio unlocks tremendous efficiency gains in team delivery and improves the collaboration experience while reducing the gap between strategy design and execution.
About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: The first unit covers the advisory business with a clear focus on five key areas to drive growth across all regions. The second unit provides IP-driven managed services beyond SaaS and offers business critical services to its clients supporting their business success. The third unit provides the software for successful digital transformation and regulatory requirements. It is also designed to explore innovative business models with clients and partners by driving the financing and development of start-ups and leveraging ecosystems.
BearingPoint's clients include many of the world's leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.
For more information, please visit:
Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint
View source version on businesswire.com: https://www.businesswire.com/news/home/20200916005793/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
